Current Perspectives for Oral Hypoglycemic Agents with Clinical Evidence of Larger Studies
DOI:
https://doi.org/10.17140/DROJ-7-e016Keywords:
Oral hypoglycemic agents (OHAs), Sodium glucose cotransporter-2 inhibitor (SGLT-2i), Semaglutide; Bullous pemphigoid (BP), Hospitalization for heart failure (HHF), Major adverse cardiovascular event (MACE)Abstract
Current reports for oral hypoglycemic agents (OHAs) are described. As to the association of dipeptidyl peptidase-4 inhibitors (DPP-
4i) and bullous pemphigoid (BP), odds ratio (OR) was vildagliptin 5.08, linagliptin 2.87, sitagliptin 1.29 (not significant). Regarding
the comparative study between SGLT2i and DPP-4i, SGLT2i group showed lower hazard ratio (HR) as MACE 0.76, myocardial
infarction 0.82, cardiovascular death 0.60, heart failure 0.43, all-cause mortality 0.60. Semaglutide showed reduced OR for cardiovasculardeath than exenatide 0.47, dulaglutide 0.46, albiglutide 0.45, lixisenatide 0.43. SGLT2i showed reduction risk of HR for MACE 0.90, hospitalization for heart failure (HHF)/cardiovascular death 0.78, renal outcomes 0.62.
References
American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetesd 2021. Diabetes Care. 2021; 44(Suppl.1): S111-S124. doi: 10.2337/ dc21-S009
Zaccardi F, Ling S, Lawson C, Davies MJ, Khunti K. Severe hypoglycaemia and absolute risk of cause-specific mortality in in-dividuals with type 2 diabetes: A UK primary care observational study. Diabetologia. 2020; 63(10): 2129-2139. doi: 10.1007/s00125- 020-05223-3
Taylor OM, Lam C. The Effect of dipeptidyl peptidase-4 inhib-Editorial | Volume 7 | Number 1 | Diabetes Res Open J. 2021; 7(1): e1-e3. doi: 10.17140/DROJ-7-e016 itors on macrovascular and microvascular complications of dia-betes mellitus: A systematic review. Curr Ther Res Clin Exp. 2020; 93: 100596. doi: 10.1016/j.curtheres.2020.100596
Silverii GA, Dicembrini I, Nreu B, Montereggi C, Mannucci E, Monami M. Bullous pemphigoid and dipeptidyl peptidase-4 inhibitors: A meta-analysis of randomized controlled trials. Endo-crine. 2020; 69(3): 504-507. doi: 10.1007/s12020-020-02272-x
Yang W, Cai X, Zhang S, Han X, Ji L. Dipeptidyl peptidase-4 inhibitor treatment and the risk of bullous pemphigoid and skin-related adverse events: A systematic review and meta-analysis of randomized controlled trials. Diabetes Metab Res Rev. 2021; 37(3): e3391. doi: 10.1002/dmrr.3391
Phan K, Charlton O, Smith SD. Dipeptidyl peptidase-4 inhibi-tors and bullous pemphigoid: A systematic review and adjusted meta-analysis. Australas J Dermatol. 2020; 61(1): e15-e21. doi: 10.1111/ajd.13100
Filion KB, Lix LM, Yu OH, Dell’Aniello S, Douros A, Shah BR, et al. Canadian Network for Observational Drug Effect Stud-ies (CNODES) Investigators. Sodium glucose cotransporter 2 in-hibitors and risk of major adverse cardiovascular events: Multi-database retrospective cohort study. BMJ. 2020; 370: m3342. doi: 10.1136/bmj.m3342
Avgerinos I, Michailidis T, Liakos A, Karagiannis T, Matthews DR, Tsapas A, et al. Oral semaglutide for type 2 diabetes: A sys-tematic review and meta-analysis. Diabetes Obes Metab. 2020; 22(3): 335-345. doi: 10.1111/dom.13899
Alfayez OM, Almohammed OA, Alkhezi OS, Almutairi AR, Al Yami MS. Indirect comparison of glucagon like peptide-1 recep-tor agonists regarding cardiovascular safety and mortality in pa-Submit your article to this journal | https://openventio.org/submit-manuscript/ Editorial | Volume 7 | Number 1 | Bando H tients with type 2 diabetes mellitus: Network meta-analysis. Car-diovasc Diabetol. 2020; 19(1): 96. doi: 10.1186/s12933-020-01070-z
Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, et al. VERTIS CV Investigators. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020; 383(15): 1425-1435. doi: 10.1056/NEJMoa2004967
McGuireDK, Shih WJ, Cosentino F, Charbonnel B, Cherney DZI, Dagogo-Jack S, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 dia-betes: A meta-analysis. JAMA Cardiol. 2021; 6(2): 148-158. doi: 10.1001/jamacardio.2020.4511
Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. DAPA-CKD trial committees and investigators. Dapagliflozin in patients with chronic kidney dis-ease. N Engl J Med. 2020; 383(15): 1436-1446. doi: 10.1056/NEJ-Moa2024816
Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. EMPEROR-reduced trial investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020; 383(15): 1413-1424. doi: 10.1056/NEJMoa2022190
Heyward J, Mansour O, Olson L, Singh S, Alexander GC. As-sociation between sodium-glucose cotransporter 2 (SGLT2) in-hibitors and lower extremity amputation: A systematic review and meta-analysis. PLoS One. 2020; 15(6): e0234065. doi: 10.1371/ journal.pone.0234065
Huang CY, Lee JK. Sodium-glucose co-transporter-2 inhibi-tors and major adverse limb events: A trial-level meta-analysis in-cluding 51 713 individuals. Diabetes Obes Metab. 2020; 22(12): 2348- 2355. doi: 10.1111/dom.14159 e3
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Diabetes Research (DR) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
